Provided by Tiger Trade Technology Pte. Ltd.

Sensei Biotherapeutics, Inc.

9.09
0.0000
Volume:2.60K
Turnover:23.98K
Market Cap:11.47M
PE:-0.47
High:9.36
Open:9.28
Low:9.09
Close:9.09
52wk High:18.35
52wk Low:5.00
Shares:1.26M
Float Shares:828.30K
Volume Ratio:0.13
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-19.1560
EPS(LYR):-24.0130
ROE:-70.18%
ROA:-37.04%
PB:0.50
PE(LYR):-0.38

Loading ...

Company Profile

Company Name:
Sensei Biotherapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
15
Office Location:
1405 Research Boulevard,Suite 125,Rockville,Maryland,United States
Zip Code:
20850
Fax:
- -
Introduction:
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Directors

Name
Position
John Celebi
Director,President and Chief Executive Officer
William Ringo
Chairman
Bob Holmen
Director
Christopher W. Gerry
Director
James Peyer
Director
Kristian Humer
Director
Phillip B. Donenberg
Director
Thomas Ricks
Director

Shareholders

Name
Position
John Celebi
Director,President and Chief Executive Officer
Josiah Craver
Senior Vice President of Finance
Edward van der Horst
Chief Scientific Officer
Stephanie Krebs
Chief Business Officer